Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REWRITe
2024-513977-31-00Phase 2Completed
- Sponsor
- GORTEC
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Primary endpoint: Regional (neck) nodal control rate at 1 year. Started Jul 2024; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513977-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513977-31-00.